Windtree Therapeutics, Inc. (WINTW) Stock Analysis
DELISTED 2026
What happened to Windtree Therapeutics, Inc. (WINTW) stock?
Windtree Therapeutics, Inc. (WINTW) no longer trades on public markets. It was delisted in March 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Windtree Therapeutics, Inc. (WINTW) trades at $0.003. Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for acute cardiovascular and pulmonary diseases. Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for WINTW: WINTW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates WINTW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
WINTW: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Windtree Therapeutics, Inc. (WINTW) Healthcare & Pipeline Overview
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in acute cardiovascular and pulmonary therapies, including istaroxime and AEROSURF. With a focus on addressing unmet needs in heart failure and respiratory distress, Windtree operates in a competitive biotechnology landscape, marked by ongoing clinical trials and strategic collaborations.
What Is the Investment Thesis for WINTW?
Windtree Therapeutics presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The primary value driver is the successful completion of clinical trials and subsequent commercialization of its lead drug candidates, particularly istaroxime for ADHF and cardiogenic shock, and AEROSURF for RDS. Positive Phase 2b results for istaroxime could significantly increase the company's valuation. However, the company's negative profit margin of -44447.8% and reliance on future funding introduce substantial financial risk. Upcoming clinical trial readouts represent key catalysts. The company's small size and OTC listing add further complexity.
Based on FMP financials and quantitative analysis
WINTW Key Highlights
Windtree Therapeutics is a clinical-stage biopharmaceutical company focused on acute cardiovascular and pulmonary diseases.
- The company's lead drug candidate, istaroxime, is in Phase 2b clinical trials for acute decompensated heart failure.
- AEROSURF, an aerosolized KL4 surfactant, is in Phase 2b development for respiratory distress syndrome in premature infants.
- Surfaxin is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19.
- The company reported a negative profit margin of -44447.8%.
Who Are WINTW's Competitors?
WINTW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 78 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| QTTB Q32 Bio Inc. | $15.86 | +0.13% | $472M | 83 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WINTW's Key Strengths?
Proprietary KL4 surfactant technology.
- Clinical-stage pipeline addressing unmet medical needs.
- Strategic collaborations with research institutions.
- Focus on acute cardiovascular and pulmonary diseases.
What Are WINTW's Weaknesses?
Limited financial resources.
- High dependence on clinical trial outcomes.
- Negative profit margin.
- OTC market listing.
What Could Drive WINTW Stock Higher?
Phase 2b clinical trial results for istaroxime in acute decompensated heart failure.
- Phase 2b clinical trial results for AEROSURF in respiratory distress syndrome.
- Phase 2a clinical trial for Surfaxin in lung injury resulting from COVID-19.
- Phase 2b clinical trial for Rostafuroxin in genetically associated hypertension.
- Advancement of oral and intravenous SERCA2a activators in preclinical development for chronic and acute heart failure.
What Are the Key Risks for WINTW?
Clinical trial failures for istaroxime, AEROSURF, or other drug candidates.
- Regulatory delays or rejection of drug approval applications.
- Limited financial resources and need for additional funding.
- Competition from established pharmaceutical companies.
- Dilution of existing shareholders through future equity offerings.
What Are the Growth Opportunities for WINTW?
- Istaroxime for Acute Decompensated Heart Failure (ADHF): Istaroxime, a SERCA2a activator, represents a significant growth opportunity in the ADHF market. Positive Phase 2b trial results could position istaroxime as a novel treatment option, potentially capturing a substantial market share. The timeline for commercialization depends on successful completion of Phase 3 trials and regulatory approval, potentially within the next 3-5 years.
- AEROSURF for Respiratory Distress Syndrome (RDS): AEROSURF, an aerosolized KL4 surfactant, targets RDS in premature infants. The RDS market is driven by the high incidence of premature births. Successful Phase 2b and Phase 3 trials could lead to AEROSURF becoming a standard-of-care treatment, offering a less invasive alternative to traditional surfactant administration. Commercialization could occur within 3-5 years following positive trial outcomes and regulatory approval.
- Surfaxin for COVID-19-Related Lung Injury: Surfaxin, a lyophilized KL4 surfactant, is being evaluated for lung injury resulting from COVID-19. The COVID-19 pandemic has highlighted the need for effective treatments for acute respiratory distress syndrome (ARDS). If Surfaxin demonstrates efficacy in clinical trials, it could address a significant unmet need. Timeline for commercialization is dependent on clinical trial results and regulatory pathways.
- Rostafuroxin for Genetically Associated Hypertension: Rostafuroxin is in Phase 2b clinical trial for the treatment of genetically associated hypertension. This represents a more targeted approach to hypertension treatment, potentially offering improved efficacy and reduced side effects for patients with specific genetic profiles. The market opportunity lies in identifying and treating patients with these genetic markers. Clinical trial success and regulatory approval are necessary for commercialization.
- SERCA2a Activators for Chronic Heart Failure: Windtree is developing oral and intravenous SERCA2a activators for chronic heart failure in preclinical trials. Chronic heart failure represents a large and growing market. These activators could offer a novel mechanism of action to improve cardiac function. Preclinical success and subsequent clinical trials are necessary before commercialization, representing a longer-term growth opportunity.
What Opportunities Does WINTW Have?
- Successful completion of clinical trials for istaroxime and AEROSURF.
- Expansion into new therapeutic areas.
- Partnerships with larger pharmaceutical companies.
- Government funding and grants for research and development.
What Are WINTW's Competitive Advantages?
- Proprietary KL4 surfactant technology platform.
- Clinical-stage pipeline with multiple drug candidates.
- Strategic collaborations with leading research institutions.
- Intellectual property protection for its drug candidates.
What Does WINTW Do?
Windtree Therapeutics, Inc., founded in 1992 and headquartered in Warrington, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for acute cardiovascular and pulmonary diseases. Originally named Discovery Laboratories, Inc., the company rebranded to Windtree Therapeutics in April 2016. Windtree's pipeline features several clinical-stage programs, including istaroxime, a SERCA2a activator in Phase 2b trials for acute decompensated heart failure (ADHF) and Phase 2a trials for early cardiogenic shock. AEROSURF, an aerosolized KL4 surfactant, is in Phase 2b development for respiratory distress syndrome (RDS) in premature infants. Surfaxin, a lyophilized KL4 surfactant, is being evaluated in a Phase 2a trial for lung injury resulting from COVID-19. Rostafuroxin is in Phase 2b clinical trial for genetically associated hypertension. Additionally, the company is advancing oral and intravenous SERCA2a activators in preclinical development for chronic and acute heart failure. Windtree has established strategic collaborations with institutions like Chang Gung University, Universita degli Studi di Milano-Bicocca, Laboratorios del Dr. Esteve, S.A., and Battelle Memorial Institute to support its research and development efforts.
What Products and Services Does WINTW Offer?
- Develops therapeutics for acute cardiovascular diseases.
- Develops therapeutics for acute pulmonary diseases.
- Focuses on treatments for acute decompensated heart failure (ADHF).
- Develops treatments for early cardiogenic shock.
- Develops treatments for respiratory distress syndrome (RDS) in premature infants.
- Develops treatments for lung injury resulting from COVID-19.
- Develops treatments for genetically associated hypertension.
How Does WINTW Make Money?
- Develops pharmaceutical products through clinical trials.
- Out-licenses or partners with other companies for commercialization.
- Collaborates with universities and research institutions for drug discovery.
- Seeks regulatory approval from health authorities like the FDA.
What Industry Does WINTW Operate In?
Windtree Therapeutics operates within the competitive biotechnology industry, focusing on cardiovascular and pulmonary therapeutics. The market for heart failure and respiratory distress treatments is substantial, driven by aging populations and increasing prevalence of these conditions. Competition includes established pharmaceutical companies and other biotech firms developing novel therapies. Windtree's success depends on demonstrating clinical efficacy and safety, securing regulatory approvals, and establishing commercial partnerships. The biotechnology industry is characterized by high R&D costs, lengthy development timelines, and regulatory hurdles.
Who Are WINTW's Key Customers?
- Hospitals and healthcare providers treating patients with acute heart failure.
- Neonatologists and hospitals treating premature infants with RDS.
- Patients suffering from lung injury due to COVID-19.
- Patients with genetically associated hypertension.
Forward Outlook
Wall Street analysts project Windtree Therapeutics, Inc. revenue of about $12.4M for fiscal 2026, with EPS near $-549.00.
Financial Health
Windtree Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Company Profile
Windtree Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Warrington, US. The company is led by CEO Jed A. Latkin. WINTW has traded publicly since 1995.
WINTW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence, suggesting those closest to the company see value.
- The community's bullish sentiment seems to stem from perceived unmet needs in the acute cardiovascular space, where Windtree operates.
- Positive market perception is building around their pipeline, with anticipation for upcoming trial results.
- Windtree's strategic focus on a specific niche within cardiovascular therapeutics could lead to significant market share if successful.
Bear Case
- Community chatter indicates skepticism about Windtree's long-term funding strategy, raising concerns about potential dilution.
- Insider activity, while showing some buying, might be interpreted as insufficient to offset existing concerns.
- Bearish sentiment within the community highlights the inherent risks associated with biotech companies and clinical trial outcomes.
- Market perception acknowledges the competitive landscape, with larger pharmaceutical companies posing a threat to Windtree's market penetration.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
WINTW Latest News
No recent news available for WINTW.
Leadership: Jed A. Latkin
Unknown
Information on Jed A. Latkin's background is not available within the provided data. Further research would be needed to provide details on his career history, education, and previous roles.
Track Record: Information on Jed A. Latkin's track record is not available within the provided data. Further research would be needed to provide details on key achievements, strategic decisions, and company milestones under his leadership.
WINTW OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Windtree Therapeutics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other tier status.
- Higher price volatility compared to stocks listed on major exchanges.
- Potential for limited liquidity and wider bid-ask spreads.
- Increased risk of fraud or manipulation.
- Lower regulatory oversight compared to listed companies.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's clinical trial results and regulatory approvals.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any history of regulatory actions or legal issues.
- Clinical-stage pipeline with multiple drug candidates in development.
- Strategic collaborations with reputable research institutions.
- Focus on addressing unmet medical needs in cardiovascular and pulmonary diseases.
- History as a publicly traded company, even if now on the OTC market.
- Presence of intellectual property protection for its drug candidates.
Windtree Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What happened to Windtree Therapeutics, Inc. (WINTW) stock?
Windtree Therapeutics, Inc. (WINTW) no longer trades on public markets. It was delisted in March 2026. The figures below are historical and are not a current quote.
Can I still buy WINTW shares?
No. WINTW stopped trading on public markets in March 2026, so the shares are not available through a broker. Anything you see quoted for WINTW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before WINTW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Windtree Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Windtree Therapeutics, Inc. do?
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute cardiovascular and pulmonary diseases. Their primary focus is on addressing unmet medical needs in conditions such as acute decompensated heart failure (ADHF), respiratory distress syndrome (RDS) in premature infants, and lung injury resulting from COVID-19.
What do analysts say about WINTW stock?
As of March 16, 2026, there is no readily available analyst consensus on Windtree Therapeutics (WINTW) due to its OTC listing and small market capitalization. The company's valuation is primarily driven by the potential success of its clinical trials, particularly for istaroxime and AEROSURF. Investors should closely monitor clinical trial results and regulatory updates.
What are the main risks for WINTW?
Windtree Therapeutics faces several key risks inherent to clinical-stage biopharmaceutical companies. The primary risk is the potential failure of its clinical trials, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining drug approvals also pose a significant risk.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 16, 2026.
- OTC market data may be limited or less reliable than major exchange data.
- AI analysis pending for WINTW.